Lantheus (NASDAQ:LNTH) Stock Price Expected to Rise, Truist Financial Analyst Says

Lantheus (NASDAQ:LNTH) had its price objective boosted by analysts at Truist Financial from $115.00 to $125.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price target points to a potential upside of 19.90% from the stock’s current price.

A number of other equities analysts have also weighed in on LNTH. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Citizens Jmp reaffirmed a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a report on Monday, June 29th. B. Riley Financial lifted their price target on Lantheus from $97.00 to $129.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $110.43.

Lantheus Stock Performance

Shares of LNTH stock traded down $0.07 during trading hours on Thursday, hitting $104.25. The company’s stock had a trading volume of 122,290 shares, compared to its average volume of 952,303. The company has a 50 day moving average of $101.82 and a 200 day moving average of $83.80. The stock has a market cap of $6.79 billion, a PE ratio of 25.14 and a beta of -0.06. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.86.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm’s revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts forecast that Lantheus will post 4.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

Hedge funds have recently modified their holdings of the company. Western Wealth Management LLC purchased a new position in Lantheus during the first quarter worth about $25,000. Smartleaf Asset Management LLC grew its stake in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares during the period. Parallel Advisors LLC increased its holdings in shares of Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares during the last quarter. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus during the 2nd quarter valued at approximately $36,000. Finally, Bessemer Group Inc. lifted its holdings in Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 354 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.